A nationwide post-marketing survey of knowledge, attitude and practice toward human papillomavirus vaccine in general population: Implications for vaccine roll-out in mainland China

Hu, Shangying; Xu, Xiaoqian; Zhang, Yanyang; Liu, Yawen; Yang, Chunxia; Wang, Yue-Yun; Wang, Yan; Yu, Yan-Qin; Hong, Ying; Zhang, Xingxing; Bian, Rui; Cao, Xian; Xu, Lili; Zhao, Fen

doi:10.1016/j.vaccine.2020.11.029

Cited by 50 publications

(40 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A survey in 2019 shows that less than 3% of women on Chinese mainland have been vaccinated. 14 HPV is one of the most common STDs worldwide, and most sexually active males and females are exposed to it during their lifetime. 19 STD clinics enable the collection of HPV epidemiological data.…”

Section: Introductionmentioning

confidence: 99%

“…In addition, Some developed countries have initiated gender-neutral immunization programs. 14 , 15 These measures in developed countries have played an important catalytic role in the popularization of HPV vaccine in developing countries. The (CFDA) of the China Food and Drug Administration approved the first HPV vaccine Cervarix (bivalent HPV) in 2016.…”

Section: Introductionmentioning

confidence: 99%

“…A survey in 2019 shows that less than 3% of women on Chinese mainland have been vaccinated. 14 …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Prevalence and Genotype Distribution of Human Papillomavirus Among Attendees at a Sexually Transmitted Diseases Clinic in Urban Tianjin, China

Xiang¹,

Han²,

Yu³

et al. 2021

IJGM

View full text Add to dashboard Cite

Background: Human papillomavirus (HPV) is linked to various cancers in males and females. The prevalence and genotype distribution of HPV vary depending on geographical region and the immunity provided by vaccines. Investigation of HPV epidemiology is of great meaning for the development of prevention programs. Methods: From January 2017 to September 2019, using PCR-reverse dot blot hybridisation, we determined the HPV subtypes in 2801 patients 17-89 years old at the sexually transmitted diseases (STD) clinic of Tianjin Medical University General Hospital. Results: The HPV infection rate was 50.79% in males and 50.64% in females. The most common HPV genotype in males and females was HPV6 (30.15% and 30.43%), followed by HPV16 (18.76% and 20.65%) and HPV11 (14.61% and 15.67%). Infection with a single HPV subtype predominated in both males and females, and the rate in males was higher than in females. By contrast, the rate of high-risk HPV (hrHPV) and low-risk HPV (lrHPV) mixed infection in females was higher than in males. Most HPV-positive patients were 20-39 years of age. The prevalence of infection with only hrHPV differed among the age groups; the peak age was 50 to 59 years. Conclusion:The HPV prevalence was higher among the STD clinic outpatients than the general population. Therefore, a large-scale survey of high-risk populations is needed. It is anticipated that HPV vaccines, regular education and physical examinations may have a significant impact on the prevention of HPV-related diseases in high-risk groups.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence and Genotype Distribution of Human Papillomavirus Among Attendees at a Sexually Transmitted Diseases Clinic in Urban Tianjin, China

Xiang¹,

Han²,

Yu³

et al. 2021

IJGM

View full text Add to dashboard Cite

show abstract

“…[8] China has implemented a relatively complete three-grade prevention strategy for CC (including primary prevention strategies that mainly comprise HPV vaccination, health education, and safe sex practices; secondary prevention strategies that mainly include CC screening and precancerous lesion treatment; and tertiary prevention strategies that mainly involve treatment of invasive CC). However, the current vaccination rate of HPV is still relatively low [9] due to the low awareness, poor availability, and high price of the vaccines. [9,10] Presently, the approved HPV vaccines in China including Cervarix ® , Gardasil ® 4, Gardasil ® 9, and Cecolin ® , which have different protective efficacies according to researches.…”

Section: Introductionmentioning

confidence: 99%

“…However, the current vaccination rate of HPV is still relatively low [9] due to the low awareness, poor availability, and high price of the vaccines. [9,10] Presently, the approved HPV vaccines in China including Cervarix ® , Gardasil ® 4, Gardasil ® 9, and Cecolin ® , which have different protective efficacies according to researches. [11,12] Also, the prices of these four kinds of vaccines are distinctly different.…”

Section: Introductionmentioning

confidence: 99%

The lifetime cost estimation of human papillomavirus-related diseases in China: a modeling study

Ding

et al. 2021

Journal of Translational Internal Medicine

View full text Add to dashboard Cite

Objectives To estimate the lifetime treatment costs of patients with human papillomavirus (HPV) infection-related diseases in China and to provide cost estimates for the economic evaluation of HPV intervention strategies. Methods We extracted real-world hospital data from 2012 to 2019 and screened for subjects who met the criteria of clinical diagnosis of HPV-related diseases to obtain country-specific inputs into a Markov decision model. The model simulated lifetime treatment costs for HPV from the perspective of a national payer. A 5% discount rate was applied. Costs were converted and inflated to 2020 US dollars (USD) Results Using 2021 as the base year, the lifetime costs per patient for carcinoma in situ, local metastasis, and distant metastasis cervical cancer are $24,208 (95%CI: 18,793–30,897), $19,562 (95%CI: 14,456–25,567), and $17,599 (95%CI: 10,604–25,807), respectively. For carcinoma in situ, local metastasis, and distant metastasis vaginal cancer, the lifetime costs are $17,593 (95%CI: 14,962–23,596), $17,120 (95%CI: 13,215–22,417), and $22,411 (95%CI: 12,172–22,249), respectively. The base-case lifetime cost per patient for different stages of vulvar cancer/penile cancer/anal cancer/oral cancer/oropharyngeal cancer/laryngeal cancer falls within $17,120–$58,236. Conclusions Using real-world data, we calculated lifetime treatment costs of HPV-related cancer in China and found that the lifetime cost for patients exceeded $17,000 for various stages of disease. The national burden of HPV-related disease could be significantly reduced by eliminating HPV infection.

show abstract

Burden of major cancers in China attributable to modifiable risk factors: Predictions from 2012 to 2035

Pei,

Li,

Lei

et al. 2024

Intl Journal of Cancer

View full text Add to dashboard Cite

The cancer burden continues to escalate in China. This study was designed to quantify the burden of deaths attributable to modifiable risk factors for major cancers in China from 2012 to 2035, and to provide evidence‐based recommendations for cancer management. Using nationally representative data on risk factors and cancer mortality, a comparative risk assessment approach was employed to calculate the temporal trend of population‐attributable fractions (PAFs) for 15 modifiable risk factors associated with major cancers in China. The PAF for modifiable risk factors decreased from 64.5% (95% uncertainty interval [UI]: 46.2%–75.3%) in 2012 to 59.3% (95% UI: 40.6%–71.2%) in 2035. Attributable deaths increased from 1,309,990 (95% UI: 938,217–1,529,170) in 2012 to 1,313,418 (95% UI: 898,411–1,577,189) in 2035, while attributable disability‐adjusted life years (DALYs) rose from 28,488,120 (95% UI: 20,471,859–33,308,237) to 33,017,705 (95% UI: 22,730,814–39,564,735). Between 2012 and 2035, the top three risk factors contributing to cancer burden shifted from smoking, insufficient fruit intake and particulate matter <2.5 μm in diameter (PM2.5) exposure to smoking, physical inactivity, and inadequate fruit intake. Controlling modifiable risk factors at recommended levels by 2020 could have prevented around 890,000 deaths and 2.2 million DALYs by 2035. The proportion of cancer burden due to modifiable risk factors is projected to decrease, but the absolute number continues to rise. Adhering to an optimal lifestyle could prevent ~40% of cancer deaths by 2035. Key modifiable risk factors including smoking, physical inactivity, and insufficient intake of fruits require high attention.

show abstract

A nationwide post-marketing survey of knowledge, attitude and practice toward human papillomavirus vaccine in general population: Implications for vaccine roll-out in mainland China

Cited by 50 publications

References 31 publications

Prevalence and Genotype Distribution of Human Papillomavirus Among Attendees at a Sexually Transmitted Diseases Clinic in Urban Tianjin, China

Prevalence and Genotype Distribution of Human Papillomavirus Among Attendees at a Sexually Transmitted Diseases Clinic in Urban Tianjin, China

The lifetime cost estimation of human papillomavirus-related diseases in China: a modeling study

Burden of major cancers in China attributable to modifiable risk factors: Predictions from 2012 to 2035

Contact Info

Product

Resources

About